The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•31 March 2026•

1 min read

IXICO to Raise £10.5 Million for AI Platform and FDA Regulatory Approval

Key Facts

1IXICO plans to raise up to £10.5 million through a combination of placings, director subscriptions, and a retail offer.

2The placing price is set at 8p per share, representing a 1.6% premium to the previous closing price.

3Funds will be used to accelerate the development of the AI-driven IXI platform and pursue US FDA regulatory approval.

Create Free Account

Version History

1 additional source confirmed this story

IXICO PLC has announced plans to raise up to £10.5 million through a combination of share placings, director subscriptions, and a retail offer. The fundraising price is set at 8p per share, representing a 1.6% premium over the previous closing price. The company intends to utilize the proceeds to accelerate the development of its AI-driven IXI platform focused on neuroscience imaging. A significant portion of the capital will also support the regulatory pathway for obtaining US FDA approval. This strategic move aims to strengthen the company’s position in the high-growth AI medical technology sector and expand its US market presence. The premium pricing of the offer reflects management's confidence in the firm's long-term valuation and technological roadmap.